Freeze and unleash: experimental combo aims to boost immune attack on aggressive breast cancer
NCT ID NCT05806385
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tests whether freezing a breast tumor (cryoablation) before giving an immunotherapy drug (PD1 inhibitor) can help the immune system better recognize and attack triple-negative breast cancer. About 36 women with early-stage, high-risk breast cancer will receive the combination before standard chemotherapy. The goal is to see if this approach increases the chance of eliminating all cancer cells by the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PD1 inhibitor (a type of immunotherapy) combined with cryoablation
What this could lead to
If it works, this combination could improve how well the immune system attacks triple-negative breast cancer, potentially leading to better tumor clearance and fewer recurrences.
What could go wrong
This is a very early (Phase 1/2) trial with only 36 participants, so results may not apply broadly. The combination could cause immune-related side effects or fail to improve outcomes over standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••